Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

The purpose of the study is to determine whether the ability of MEK162 to antagonize MEK activation in NS HCM patients, who usually have upstream mutations in the Ras-Raf-Mek-Erk pathway that lead to MEK activation, would be beneficial over a 6 month treatment period in hypertrophy regression.

Study Overview

• Status: Withdrawn
• Conditions: Cardiomegaly
• Intervention / Treatment: Drug: MEK162

Detailed Description

This study is designed as a proof of concept of MEK162 in NS HCM patients. The purpose of the present study is to determine whether the ability of MEK162 to antagonize MEK activation in NS HCM patients, who usually have upstream mutations in the Ras-Raf-Mek-Erk pathway that lead to MEK activation, would be beneficial over a 6 month treatment period by causing hypertrophy regression. Such regression might result in cardiovascular clinical benefits with longer term treatment.

The information gained from this study will be three fold:

1. the safety/tolerability of treatment with MEK162 over 6 month in the NS HCM patient population
2. the pharmacokinetics and pharmacodynamics of MEK162 in the target patient population
3. proof of the therapeutic concept that MEK inhibition will reduce cardiac hypertrophy in the target NS HCM patient population

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, W1G 8PH
    • Pfizer Investigative Site
• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Pfizer Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion:

• Male and female Noonan syndrome patients with confirmed cardiac hypertrophy, age 18 to 65 years of age included, and in general good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
• Cardiac hypertrophy is defined by left ventricular wall thickness greater than or equal to 12 mm by echocardiography or MRI, or the change in wall thickness is accompanied by an associated increase in left ventricular mass which is defined by echo or MRI as greater than 134 g/m2 and 110 g/m2 in men and women, respectively.
• Subjects must weigh at least 45 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 34 kg/m2.

Exclusion criteria:

• Primary Long QT syndrome or a history of significant ECG abnormalities judged by the investigators to be inappropriate for participation in the current study.
• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
• Sexually active males must use a condom during intercourse while taking the drug during treatment, for 5 half lives after stopping treatment and should not father a child in this period.
• Use of any prescription drugs other than beta-blockers, diuretics, CCB, amiodarone, disopyramide, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. If needed, (i.e. an incidental and limited need) paracetamol or acetaminophen is acceptable, but must be documented in the Concomitant medications/Significant non-drug therapies page of the eCRF.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MEK162; Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.	Drug: MEK162

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Left ventricular mass (LVM)	Change in LVM after 3 months and 6 months of treatment using magnetic resonance imaging.	Baseline to 3 months and 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Cardiac energetics state at 3 months and 6 months	Energetic state represented by phosphocreatine (PCr)/adenosine triphosphate (ATP) ratio using magnetic resonance spectroscopy.	Baseline to 3 months and 6 months
Number of patients with adverse events, serious adverse events and death	Abnormalities in Vital signs, ECG evaluations, clinical laboratory evaluations, will be collected.	6 months
Pharmacokinetics of MEK162 and metabolite (AR00426032): The trough plasma concentration (Ctrough) just prior to drug administration	pre-dose concentration of MEK162 and its metabolite (AR00426032) in plasma. All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Days 1, 8, 15, 28, 56, 84, 140 and 182
Pharmacokinetics of MEK162 and metabolite (AR00426032): maximum drug exposure of MEK162 and its metabolite (AR00426032) in plasma	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Pharmacokinetics of MEK162 and metabolite (AR00426032): time to reach peak concentration (Tmax) in plasma	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to 12 hours post dose (AUC0-12h)	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to the last quantifiable sample (AUClast)	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Pharmacokinetics of MEK162 and metabolite (AR00426032): accumulation ratio (Racc)	Comparison of the drug exposures as AUCs and Cmax of MEK162 and its metabolite (AR00426032) in plasma after 8 days treatment in relation to the data from the first day (Day 8/Day 1)	Day 1 and Day 8
Pharmacokinetics of MEK162: The degree of fluctuation of MEK162 and its metabolite (AR00426032) in plasma at steady state (on Day 8)	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein. The dgree of fluctuation is calculated as (Cmax,ss - Cmin,ss)/Cav,ss at steady state.	Day 8
Pharmacokinetics of MEK162: The ratio of Metabolite (AR00426032) to MEK162 in plasma on Days 1 and 8	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Change from baseline in end systolic and end diastolic right and left vetricular volumes in 3 and 6 months	These parameters are derived from cine breath-hold magnetic resonance images acquired over the cardiac cycle.	baseline to 3 and 6 months of treatment
Pharmacokinetics of MEK162 and metabolite (AR00426032):observed maximum plasma concentration (Cmax) following drug adminstration	All blood samples will be taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein.	Day 1 and Day 8
Change from baseline in stroke volume and stroke output during 3 and 6 months	These parameters are derived from cine breath-hold magnetic resonance images acquired over the cardiac cycle.	baseline to 3 and 6 months of treatment
Ejection fraction	This parameter is derived from cine breath-hold magnetic resonance images acquired over the cardiac cycle.	baseline, 3 and 6 months of treatment
Cardiac index	This parameters is derived from cine breath-hold magnetic resonance images acquired over the cardiac cycle.	baseline, 3 and 6 months of treatment

Collaborators and Investigators

• Sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Anticipated): May 1, 2017

Study Registration Dates

• First Submitted: March 15, 2012
• First Submitted That Met QC Criteria: March 15, 2012
• First Posted (Estimate): March 16, 2012

Study Record Updates

• Last Update Posted (Actual): October 6, 2020
• Last Update Submitted That Met QC Criteria: October 2, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Noonan Syndrome, hypertrophic cardiomyopathy.
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Congenital Abnormalities; Musculoskeletal Diseases; Connective Tissue Diseases; Pathological Conditions, Anatomical; Aortic Valve Disease; Heart Valve Diseases; Heart Defects, Congenital; Cardiovascular Abnormalities; Craniofacial Abnormalities; Musculoskeletal Abnormalities; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Hypertrophy; Cardiomyopathies; Cardiomegaly; Cardiomyopathy, Hypertrophic; Noonan Syndrome
• Other Study ID Numbers: CMEK162Y2201; 2011-003392-10 (EudraCT Number)